FHA
ITCI

First Horizon Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

First Horizon Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-148
Closed -$19.5K – 2538
2025
Q1 		$19.5K Sell
148
-174
-54% -$21.7K ﹤0.01% 1339
2024
Q4 		$26.9K Buy
322
+51
+19% +$4.19K ﹤0.01% 1219
2024
Q3 		$19.8K Hold
271
– – ﹤0.01% 1358
2024
Q2 		$18.6K Buy
271
+87
+47% +$6.03K ﹤0.01% 1304
2024
Q1 		$12.7K Hold
184
– – ﹤0.01% 1502
2023
Q4 		$13.2K Hold
184
– – ﹤0.01% 1491
2023
Q3 		$9.58K Hold
184
– – ﹤0.01% 1529
2023
Q2 		$11.7K Hold
184
– – ﹤0.01% 1482
2023
Q1 		$9.96K Hold
184
– – ﹤0.01% 1562
2022
Q4 		$9.74K Hold
184
– – ﹤0.01% 1575
2022
Q3 		$8K Sell
184
-56
-23% -$2.92K ﹤0.01% 1623
2022
Q2 		$13K Buy
+240
New +$13.6K ﹤0.01% 1489
2022
Q1 		– Sell
-161
Closed -$7K – 2360
2021
Q4 		$7K Buy
+161
New +$6.76K ﹤0.01% 1671

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

First Horizon Advisors's ITCI Position: Q2 2025 in Review

First Horizon Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 148 shares — an estimated $19.5K sold.

First Horizon Advisors first reported a position in ITCI in Q4 2021 and held it in 13 quarters. The position peaked at $26.9K in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • First Horizon Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • First Horizon Advisors sold 148 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $19.5K.
  • First Horizon Advisors first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 13 quarters.
  • First Horizon Advisors's Intra-Cellular Therapies Inc. position peaked at $26.9K in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.